Genprex, Inc.
Genprex, Inc. (GNPX): 7 pipeline candidates · 6 upcoming catalysts · ~18 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.5 months
D/E 0.20 · 0% dilution
Lead: Phase 1/Phase 2
7 candidates
6 upcoming, next in ~12d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Genprex, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.0M
Cash
$18.0M
Quarterly Burn
$3.1M
Runway
17.5 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| gpx-002 | Preclinical |
| investigator's treatment of choice | Phase 1 |
| osimertinib | Phase 1/Phase 2 |
| platinum-based chemotherapy | Phase 1/Phase 2 |
| quaratusugene ozeplasmid | Phase 1 |
| ramucirumab | Phase 1 |
| reqorsa | Phase 2 |
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
22
Total value held
$127K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 33,372 | $60K |
| manchester financial inc | 20,000 | $36K |
| vanguard capital management llc | 11,900 | $22K |
| jones financial companies lllp | 2,105 | $4K |
| citigroup inc | 2,039 | $4K |
| osaic holdings, inc. | 232 | $417 |
| bernard wealth management corp. | 200 | $362 |
| blackrock, inc. | 188 | $340 |
| harbour investments, inc. | 120 | $218 |
| sbi securities co., ltd. | 48 | $87 |
Showing top 10 of 22 institutional holders of Genprex, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Genprex, Inc.'s pipeline?
Genprex, Inc. (GNPX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Genprex, Inc.'s lead drug candidate?
Genprex, Inc.'s most advanced tracked candidate is gpx-002 (Preclinical) for Type 1 diabetes and Type 2 diabetes.
What is Genprex, Inc.'s next catalyst?
Genprex, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: reqorsa" — expected June 30, 2026.
What is Genprex, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Genprex, Inc. has approximately 17.5 months of cash runway.
What is Genprex, Inc.'s market capitalization?
Genprex, Inc.'s market capitalization is approximately $5.0M.
Get the full picture on Genprex, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.